Philogen SpAMIL:PHIL +2.19%62 Gross Margin % is 98.85% as of Dec. 2025, which is 14% above its 10-year median of 86.48. GuruFocus rates MIL:PHIL with a GF Score™ of 62/100 and a GF Value™ of €227.22 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 737 Biotechnology companies, Philogen SpA ranks better than 95.66% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Philogen SpA had a gross margin of 98.85% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Philogen SpA Gross Margin % Related Terms
Philogen SpA Gross Margin % Historical Data
* Premium members only.
The historical data trend for Philogen SpA's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:PHIL vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Philogen SpA's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Philogen SpA Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Philogen SpA's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Philogen SpA's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Philogen SpA (MIL:PHIL) has a Gross Margin % of 98.85% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Philogen SpA and its competitors. This is 14% above median its historical median of 86.48. Over the past decade, Philogen SpA's Gross Margin % has ranged from 33.81 to 98.31. According to the industry distribution chart, Philogen SpA ranks #32 out of 737 companies in the Biotechnology industry, placing it in the top 4.3%.
Is Philogen SpA's Gross Margin % too high?
Philogen SpA's current Gross Margin % of 98.85% is 14% above median its 10-year median of 86.48. Over the past 10 years, this metric has ranged from a low of 33.81 to a high of 98.31. The Biotechnology industry median Gross Margin % is 60.92. Philogen SpA's value of 98.85% is 62.3% above this industry median. Based on the distribution chart, Philogen SpA ranks #32 out of 737 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Philogen SpA has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Philogen SpA's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Philogen SpA ranks #32 out of 737 companies for Gross Margin %. This places Philogen SpA in the top 4% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.92. Philogen SpA's value of 98.85% is 62.3% above this benchmark. Historically, Philogen SpA's own Gross Margin % has ranged from 33.81 to 98.31 over the past decade. While the company's 10-year median is 86.48 vs. the industry median of 60.92, Philogen SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Philogen SpA's current Gross Margin % of 98.85% is 62.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Philogen SpA and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Philogen SpA's current Gross Margin % is 98.85%, which is 14% above median its own 10-year median of 86.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Philogen SpA stock overvalued right now?
Based on GuruFocus' analysis, Philogen SpA (MIL:PHIL) is currently considered Possible Value Trap. The stock's GF Value™ is €227.22, compared to a current price of €23.25 — trading 89.8% below its estimated fair value. The current Gross Margin % is 98.85%, which is 14% above median its 10-year median of 86.48 and 62.3% above the Biotechnology industry median of 60.92. Philogen SpA's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Philogen SpA (MIL:PHIL), the current Gross Margin % is 98.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Philogen SpA (MIL:PHIL) Overvalued in 2026?
Based on GuruFocus' analysis, Philogen SpA stock appears to be undervalued.
The current stock price of €23.25 is trading 89.8% below its estimated GF Value™ of €227.22.
GuruFocus considers Philogen SpA to be Possible Value Trap.
Key valuation signals for MIL:PHIL:
Gross Margin %: 98.85% (14% above median its 10-year median of 86.48)
GF Value™: €227.22 vs. price of €23.25 (89.8% below fair value)
Industry Position: 62.3% above the Biotechnology median (#32 of 737)
No single metric tells the full story. See the MIL:PHIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
62GF Score
Get the complete analysis for MIL:PHIL
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:PHIL has been successfully added to your 
